Apimeds Pharmaceuticals US, Inc. filed a Form 8-K on September 23, 2026, disclosing that a 1-for-10 reverse stock split of its common stock became effective at 12:01 a.m. Eastern Time on July 24, 2026, following a Certificate of Amendment filed with the Delaware Secretary of State on July 23, 2026.
Key Highlights
- Reverse split ratio: One-for-ten (1-for-10), effective July 24, 2026 at 12:01 a.m. Eastern Time.
- Share count change: Shares outstanding went from 15,091,180 immediately before the split to 1,509,118 immediately after.
- Fractional share rounding: An additional 33,506 shares were issued to accommodate rounding up of fractional shares at the beneficial holder level through the Depository Trust Company.
- Par value reduction: Par value of common stock was reduced from $0.01 per share to $0.001 per share as part of the Charter Amendment.
- Authorized shares unchanged: The number of authorized shares of common stock remains at 100,000,000 and authorized preferred stock remains at 10,000,000.
- New CUSIP: The new CUSIP number for the company's common stock following the reverse stock split is 03771D201.
- Stockholder approval: Stockholders holding a majority of the voting power approved the reverse stock split by written consent on December 1, 2025.
Apimeds Pharmaceuticals Reverse Stock Split Details and Charter Amendment
According to the filing, Apimeds Pharmaceuticals US, Inc. (NYSE American:APUS) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Delaware Secretary of State on July 23, 2026. The amendment effected two changes: a 1-for-10 reverse stock split of issued and outstanding common stock, and a reduction of the par value of common stock from $0.01 per share to $0.001 per share. The company disclosed that the reverse stock split became effective at 12:01 a.m. Eastern Time on July 24, 2026, and that common stock began trading on a split-adjusted basis on the NYSE American LLC under the symbol "APUS" at the open of trading on that date.
As a result of the reverse stock split, the filing states that every ten shares of issued and outstanding common stock were automatically combined into one share. No fractional shares were issued; stockholders who would otherwise have been entitled to a fractional share received one whole share in lieu thereof. Immediately prior to the split, there were 15,091,180 shares outstanding; immediately following, there were 1,509,118 shares outstanding. The company further disclosed that an additional 33,506 shares were subsequently issued to accommodate rounding up of fractional shares at the beneficial holder level through the Depository Trust Company.
The filing also noted that proportionate adjustments were made to the number of shares underlying outstanding equity awards and warrants, and to the exercise prices thereof. The total number of authorized shares of common stock and preferred stock was not changed by the amendment, remaining at 100,000,000 and 10,000,000, respectively. The company reported that stockholder approval was obtained by written consent on December 1, 2025, and that an information statement was filed and mailed to stockholders pursuant to Rule 14c-2 under the Securities Exchange Act of 1934, as amended.
What Was Disclosed
Apimeds Pharmaceuticals US, Inc. reported a 1-for-10 reverse stock split effective July 24, 2026, reducing outstanding shares from 15,091,180 to 1,509,118, lowering par value to $0.001 per share, and assigning a new CUSIP number of 03771D201, while leaving authorized share counts unchanged.



Please wait processing your request...